Q4 & FY22 Highlights

FY22 Snapshot 32.0% INR 2087.4 Cr Revenues 34.5% INR 1691.3 Cr Non Covid Revenues Margin 34.7% 27.3 Mn 28.8% INR 600.4 Cr Patients Normalised EBITDA* 32.7% 66.0 Mn Margin 17.7% INR 369.1 Cr Samples Normalised PAT** *Normalised EBITDA excl. RSU, CSR **Normalised PAT excl. notional depreciation on consolidation of Suburban Note: Results includes Suburban Diagnostics 24 Dr Lal PathLabs

View entire presentation